Gritstone Oncology Signs R&D Deal with bluebird bio and Files for $80 Million IPO bluebird bio to pay $30 million upfront for 10 of Gritstone's tumor-specific targets and T-cell receptors (Image: Gritstone Oncology). 3 MIN READ 08.23.2018
Regeneron and bluebird bio to Collaborate on Cancer Immunotherapy Regeneron also investing $100 million in bluebird bio at 59% premium to Aug. 3rd closing price. 3 MIN READ 08.6.2018
Casma Therapeutics Launches with $58.5 Million from Third Rock Ventures Boosting autophagy -- cells breaking down and recycling components -- to stop disease (Image: Britannica) 3 MIN READ 05.3.2018
Unity Biotechnology Files for IPO for Age-Associated Disease Drug Development Targeting cellular senescence with programs in musculoskeletal, ophthalmologic and pulmonary disorders. 3 MIN READ 04.6.2018
Cellular Biomedicine Group (CBMG): Developing CAR-T Cancer Therapies in the World’s Largest Market Cellular Biomedicine Group is developing therapies to treat cancer and other degenerative diseases in China. 5 MIN READ 07.14.2017
bluebird bio Gets its Wings on Rare Drug Trial Results Cambridge, Massachusetts-based bluebird bio (BLUE) soared to an all-time intraday high in Monday action after releasing positive preliminary clinical trial data for its experimental gene therapy 3 MIN READ 06.16.2014
